The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Diagnostic and Statistical Manual of Mental Disorders
&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,526
(1976) · Medical Entomology and Zoology · Cited by 8,899
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Self-citationThe behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
Moore, N. A., Tye, N. C., Axton, M. S., & Risius, F. C. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10792-1 · Cited by 278
Clozapine: neuroleptic-induced EPS and tardive dyskinesia
Casey, D. E. (1989) · Psychopharmacology · doi:10.1007/bf00442559 · Cited by 251
Dopamine receptor pharmacology.
Seeman, P., & Tol, H. H. M. V. (1993) · PubMed · Cited by 134
Cited by
LEUCHT, S., KANE, J., KISSLING, W., HAMANN, J., ETSCHEL, E., & ENGEL, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.008 · Cited by 1,226
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,034
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Leucht, S., Pitschel-Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 796
Tran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
Self-citationDo Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
(1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401003 · Cited by 615
Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationOlanzapine: Pharmacokinetic and Pharmacodynamic Profile
Callaghan, J. T., Bergstrom, R. F., Ptak, L. R., & Beasley, C. M. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199937030-00001 · Cited by 544
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Daniel, D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00090-6 · Cited by 377
Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method
Leucht, S., Samara, M., Heres, S., Patel, M. X., Woods, S. W., & Davis, J. M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu001 · Cited by 372
5-HT2and D2Receptor Occupancy of Olanzapine in Schizophrenia: A PET Investigation
Kapur, S., Zipursky, R. B., Remington, G., Jones, C., DaSilva, J., Wilson, A. A., & Houle, S. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.921 · Cited by 370
van Reekum, R., Stuss, D. T., & Ostrander, L. (2005) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.17.1.7 · Cited by 360
Linking the PANSS, BPRS, and CGI: Clinical Implications
Leucht, S., Kane, J. M., Etschel, E., Kissling, W., Hamann, J., & Engel, R. R. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301147 · Cited by 333
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Effects of Newer Antipsychotics on Extrapyramidal Function
Tarsy, D., Baldessarini, R. J., & Tarazi, F. I. (2002) · CNS Drugs · doi:10.2165/00023210-200216010-00003 · Cited by 313
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.9.1248 · Cited by 280
Schizophrenia: from phenomenology to neurobiology
Wong, A. H. C., & Van Tol, H. H. M. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00035-6 · Cited by 280
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Keck Jr, P., Buffenstein, A., Ferguson, J., Feighner, J., Jaffe, W., Harrigan, E. P., & Morrissey, M. R. (1998) · Psychopharmacology · doi:10.1007/s002130050755 · Cited by 265
How to obtain nnt from cohen’s D: comparison of two methods
Furukawa, T. A., & Leucht, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019070 · Cited by 179
Passik, S. D., Lundberg, J., Kirsh, K. L., Theobald, D., Donaghy, K., Holtsclaw, E., Cooper, M., & Dugan, W. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00391-3 · Cited by 154
Kane, J. M., Cohen, M., Zhao, J., Alphs, L., & Panagides, J. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d35d6b · Cited by 126
Berwaerts, J., Cleton, A., Rossenu, S., Talluri, K., Remmerie, B., Janssens, L., Boom, S., Kramer, M., & Eerdekens, M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106914 · Cited by 49
Metadata
- Authors
- Beasley, C. M., Sanger, T., Satterlee, W., Tollefson, G., Tran, P., & Hamilton, S.
- Venue
- Psychopharmacology
- Published
- 1996-03
- Volume
- 124
- Issue
- 1-2
- Pages
- 159-167
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2070735132
- Cited by
- 390
- References
- 12
- FWCI
- 30.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.